Medine.co.uk

Lignol 2.0% W/V Solution For Injection

Revised: December 2012

AN: 01020/2012


SUMMARY OF PRODUCT CHARACTERICTICS


1. Name of Veterinary Medicinal Product


Lignol 2.0 % w/v Solution for Injection


2. Qualitative and Quantitative Composition


Active ingredients % w/v


Lidocaine hydrochloride / Lignocaine hydrochloride 2.0

Adrenaline acid tartrate*/ Epinephrine acid tartrate 0.00198


*Including a 10 % manufacturing overage


For a full list of excipients, see section 6.1.


3. Pharmaceutical Form


Solution for injection.

Sterile, aqueous solution.


4. Clinical Particulars


4.1 Target species


Cats, dogs and horses.


4.2 Indications for use, specifying the target species


A local anaesthetic agent for regional nerve block, paravertebral nerve block and infiltration anaesthesia, for use in cats, dogs and horses.


4.3 Contraindications


Do not use in cardiac or hepatic insufficiency.


Special warnings for each target species


None.


Special precautions for use


Special precautions for use in animals


Do not administer by intravenous injection.


Do not use for more than one induction of anaesthesia in any 24 hours.


Special precautions to be taken by the person administering the veterinary medicinal product to animals


Following accidental self injection or ingestion seek medical advice taking the vial with you. Following eye contamination or excessive skin contact, irrigate/wash thoroughly with cold running water. Seek medical advice if irritation persists.


Other precautions


None.


4.6 Adverse reactions (frequency and seriousness)


None known.


4.7 Use during pregnancy, lactation or lay


Use with caution in pregnant animals.


4.8 Interaction with other medicinal products and other forms of interaction


None known.


4.9 Amounts to be administered and administration route


For local nerve block by subcutaneous injection.


Cat infiltration 1 ml

Dog infiltration 1-2 ml

Horse infiltration 50 ml max


For paravertebral block up to 10 ml each nerve.


4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary


Local anaesthetics may have systemic adverse effects as a result of the raised plasma concentrations which occur when the rate of absorption exceeds the rate of breakdown. Toxicity causes excitation of the central nervous system, which may be followed by systemic depression leading to coma. Convulsions may be controlled with Diazepam.


4.11 Withdrawal periods


Horse meat: zero days.


5. Pharmacological Particulars


Pharmacotherapeutic group: Lidocaine, combinations


ATC Vet Code: QN01BB52


Pharmacodynamic properties


Lidocaine is a local anaesthetic of the amide type, used both by injection and for local application to mucous membranes.


5.2 Pharmacokinetic properties


Lidocaine has rapid onset of action when injected and spreads rapidly through surrounding tissues. The speed of onset and duration of action of Lidocaine may be increased by the addition of a vasoconstrictor.


Adrenaline is added to local anaesthetics, such as Lidocaine hydrochloride, to slow diffusion and limit absorption as it constricts arterioles and capillaries, so prolonging the duration of the effect and lessening the danger of toxicity.


6. Pharmaceutical Particulars


6.1 List of excipients


Sodium chloride

Sodium metabisulphite

Chlorocresol

Water for injections


6.2 Incompatibilities


None known.


Shelf life


Shelf life of the veterinary medicinal product as packaged for sale: 2 years.


Shelf life after first opening the immediate packaging: 28 days.


6.4 Special precautions for storage


Do not store above 25°C.

Discard unused material.


6.5 Nature and contents of immediate packaging


100 ml neutral amber glass vial fitted with a red rubber plug and an aluminium seal, containing a sterile, aqueous solution.


6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate


Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

MARKETING AUTHORISATION HOLDER


Dechra Limited

Dechra House

Jamage Industrial Estate

Talke Pits

Stoke-on-Trent

Staffordshire

ST7 1XW

UK


8. MARKETING AUTHORISATION NUMBER


Vm 10434/4028


DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION


Date of first authorisation: 31 August 1993

Date of renewal of the authorisation: 31 August 2003


DATE OF ANY REVISION OF THE TEXT


Date: December 2012


Approved:

19/12/12

Page 4 of 4